NASDAQ:ADVM - Adverum Biotechnologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.94 +0.25 (+6.78 %)
(As of 12/12/2018 12:37 PM ET)
Previous Close$3.69
Today's Range$3.75 - $3.94
52-Week Range$2.62 - $8.59
Volume1,704 shs
Average Volume883,821 shs
Market Capitalization$228.84 million
P/E Ratio-3.03
Dividend YieldN/A
Beta3.79
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADVM
Previous Symbol
CUSIPN/A
Phone650-272-6269

Debt

Debt-to-Equity RatioN/A
Current Ratio22.08
Quick Ratio22.08

Price-To-Earnings

Trailing P/E Ratio-3.03
Forward P/E Ratio-3.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.85 million
Price / Sales133.90
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.09 per share
Price / Book0.96

Profitability

EPS (Most Recent Fiscal Year)($1.29)
Net Income$-56,140,000.00
Net Margins-3,582.48%
Return on Equity-30.38%
Return on Assets-28.67%

Miscellaneous

Employees78
Outstanding Shares62,870,000
Market Cap$228.84 million
OptionableOptionable

Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies Inc (NASDAQ:ADVM) posted its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.04. The biotechnology company earned $0.83 million during the quarter, compared to the consensus estimate of $0.27 million. Adverum Biotechnologies had a negative net margin of 3,582.48% and a negative return on equity of 30.38%. View Adverum Biotechnologies' Earnings History.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Adverum Biotechnologies.

What price target have analysts set for ADVM?

5 brokerages have issued 12-month price targets for Adverum Biotechnologies' shares. Their forecasts range from $4.00 to $11.00. On average, they expect Adverum Biotechnologies' stock price to reach $6.8750 in the next year. This suggests a possible upside of 78.1% from the stock's current price. View Analyst Price Targets for Adverum Biotechnologies.

What is the consensus analysts' recommendation for Adverum Biotechnologies?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adverum Biotechnologies.

What are Wall Street analysts saying about Adverum Biotechnologies stock?

Here are some recent quotes from research analysts about Adverum Biotechnologies stock:
  • 1. According to Zacks Investment Research, "Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California. " (11/15/2018)
  • 2. Cantor Fitzgerald analysts commented, ". We are downgrading and reducing our 12-month PT to $4 from $12. The new PT is solely based on the ADVM-022 wAMD program, soon to enter P1 testing in 2018. Our changed perspective results from the PR Friday that the company discontinued development of lead asset ADVM-043 for treatment of A1AT deficiency and hit pause on the preclinical HAE program, deciding not to file an IND in 4Q18. Although further clarity on rare disease programs is expected in 1H19, we now see only the wAMD program as a potential driver of value over the next ~12-18 months." (11/4/2018)
  • 3. Chardan Capital analysts commented, "We had previously expressed concerns on ADVM-043. In our 9 August 2018 research, we stated [t]hus even if safety signals are reassuring, there may be some question on efficacy in final data." Based on the failure of DTX101, and uncertainty on the liver tropism of AAVrh10, we saw issues with the design of ADMV-043. Further, a serious of previous failures of AAV-based GT for A1AT from other organizations including AGTC (Neutral) suggest this is a difficult indication to treat with GT. We look for better datasets in the remaining Adverum pipeline. The OPTIC phase I trial of ADVM-022, an AAV7m8-based, intravitreal anti- VEGF GT for wet AMD, is due to begin dosing in 4Q18. 2018 research detailed our concerns on this asset." (11/2/2018)

Has Adverum Biotechnologies been receiving favorable news coverage?

Media coverage about ADVM stock has trended positive this week, according to InfoTrie. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adverum Biotechnologies earned a news impact score of 2.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Who are some of Adverum Biotechnologies' key competitors?

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the folowing people:
  • Dr. Mehdi Gasmi, Pres & Chief Scientific Officer (Age 51)
  • Dr. Mitchell H. Finer, Co-Founder & Director (Age 59)
  • Dr. Amber Salzman, Consultant (Age 56)
  • Ms. Leone D. Patterson, CEO, CFO & Director (Age 55)
  • Ms. Katherine Bock, VP of Investor Relations & Corp. Communications

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.89%), Renaissance Technologies LLC (5.63%), JPMorgan Chase & Co. (4.41%), JPMorgan Chase & Co. (4.40%), Vanguard Group Inc. (3.57%) and Dimensional Fund Advisors LP (2.61%). View Institutional Ownership Trends for Adverum Biotechnologies.

Which institutional investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, FMR LLC, Man Group plc and Virtus ETF Advisers LLC. View Insider Buying and Selling for Adverum Biotechnologies.

Which institutional investors are buying Adverum Biotechnologies stock?

ADVM stock was acquired by a variety of institutional investors in the last quarter, including WS Management Lllp, BlackRock Inc., Marshall Wace North America L.P., Primecap Management Co. CA, JPMorgan Chase & Co., JPMorgan Chase & Co., Renaissance Technologies LLC and AQR Capital Management LLC. View Insider Buying and Selling for Adverum Biotechnologies.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $3.86.

How big of a company is Adverum Biotechnologies?

Adverum Biotechnologies has a market capitalization of $228.84 million and generates $1.85 million in revenue each year. The biotechnology company earns $-56,140,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Adverum Biotechnologies employs 78 workers across the globe.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is http://www.adverum.com.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 1035 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-272-6269 or via email at [email protected]


MarketBeat Community Rating for Adverum Biotechnologies (NASDAQ ADVM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  229 (Vote Underperform)
Total Votes:  448
MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote "Outperform" if you believe ADVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel